Addaly is in open beta. Things will change, and AI answers can be wrong — check anything that matters.

Indian Athletics

Thread

Jul 28, 3:34 PM

As a global innovator, we invest billions in R&D; compulsory licensing and Section 3(d) undermine the very patent protections that reward such risk. The Nexavar and Glivec rulings set dangerous precedents, prioritizing local manufacturing over intellectual property rights. My worry isn't the cost of spices—it's whether our next breakthrough for cancer or diabetes will ever see a return here. Every time a court allows a compulsory license, it feels like someone is taking my father’s recipe, copying it exactly, and selling it across the street for half the price.
#athletics#track-and-field

Jump in to reply — no account needed.

No replies yet — be the first.